FLT3 and acute myeloid leukemia: Standard therapy had a limited efficacy of a 30–40% cure rate, and it was found that FLT3-ITD mutations had a high relapse rate and short relapse-free duration in AML patients, thus decreasing post-chemotherapy and post-transplant survival rates [28].